Terminology Service for NFDI4Health
All terms in NCIT
| Label | Id | Description |
|---|---|---|
| Mibefradil Dihydrochloride | NCIT_C87687 | |
| Meproscillarin | NCIT_C87688 | |
| Varespladib Sodium | NCIT_C73040 | [An intravenously administered inhibitor of secretory phospholipase A2 (sPLA2) with orphan drug designation. Varespladib is in trial for prevention of Acute Chest Syndrome in the treatment of sickle cell disease.] |
| Sinefungin | NCIT_C73041 | [A natural nucleoside related to S-adenosylmethionine that has been isolated from Streptomyces species with antifungal, antiviral and antiparasitic activity. Sinefungin inhibits DNA methyltransferase which leads to an inhibition of DNA synthesis.] |
| Alinastine | NCIT_C73042 | |
| Barmastine | NCIT_C73043 | |
| Ticalopride | NCIT_C73037 | |
| Sitaxentan | NCIT_C73038 | |
| Endothelin Receptor Type A Antagonist | NCIT_C28334 | [A group of agents that bind to the endothelin-1 receptor (primarily endothelin-A receptor, or ET-A), thereby inhibiting tumor cell proliferation and tumor associated angiogenesis. (NCI04)] |
| Daglutril | NCIT_C73039 | |
| Balazipone | NCIT_C73033 | |
| Alpiropride | NCIT_C73034 | |
| Bromopride | NCIT_C73035 | |
| Nemonapride | NCIT_C73036 | |
| Netazepide | NCIT_C87692 | [An orally active, benzodiazepine type, selective cholecystokinin B receptor (CCKBR; CCK2R; gastrin receptor) antagonist with potential gastric acid reducing and antiproliferative activity. Upon administration, netazepide, selectively binds to and blocks the CCKBR, thereby preventing the binding of gastrin and cholecystokinin. This may prevent gastric neuroendocrine enterochromaffin-like (ECL) cell-induced secretion of histamine, ultimately preventing gastric acid secretion from adjacent parietal cells. In addition, YF476 may inhibit ECL cell proliferation and ECL-derived gastric carcinoids.] |
| Tazomeline | NCIT_C87693 | |
| Famiraprinium | NCIT_C87694 | |
| Fencamfamin | NCIT_C87695 | |
| Phytate Sodium | NCIT_C87690 | |
| Chelating Agent | NCIT_C360 |